Talus Bio

Discovering drugs that target the DNA regulome

Director of Translational Cancer Biology at Talus Bio

Location
Seattle
Job Type
Full-time
Experience
6+ years
Connect directly with founders of the best YC-funded startups.
Apply to role ›
Alex Federation
Alex Federation
Founder

About the role

Role Description

We are seeking a Translational Cancer Biologist to join Talus Bio in a full-time position. They will work within our small team to leverage our platform to enable drug discovery for oncogenic transcription factors. We are looking for a scientific principle interested in solving complex problems in a fast-paced, innovative, early-stage biotech environment.

Responsibilities

Direct and execute research for hit-to-lead and lead optimization of our drug programs towards clinical development candidates. This includes the generation, analysis, and interpretation of diverse biological data sets related to PK/PD, gene expression, and chromatin dynamics. Build and lead a high-performing team with an inclusive and innovative culture. A key aspect of the position is to manage internal and external employees and collaborate with our platform team to optimize lead compounds. Expand the discovery research portfolio into new gene regulation targets. Manage contract research organizations (CROs) in the conduct of in vitro/in vivo pharmacology studies Effectively communicate and interact with leaders across the organization. Qualifications

Required

Ph.D. in molecular biology, cancer biology, chemical biology or other related field 5-10+ years of experience in the drug discovery industry with experience in designing, developing, performing, and analyzing cell-based assays and in vivo experiments. Experience managing and mentoring teams of Ph.D. and non-PhD scientists, as well as managing external CRO scientists. A track record of working within project teams leading to the successful delivery of clinical development candidates. Deep knowledge of cancer biology including in vitro and in vivo preclinical models. Passion to be at the forefront of drug discovery as demonstrated by a history of evaluating novel technologies to enhance drug discovery. Publication record, including patents, commensurate with the years of experience Preferred

Experience in an early-stage biotechnology start-up environment Experience in any of the following fields: Gene regulation or epigenetics Mass spectrometry proteomics Chemoproteomics and covalent approaches to protein inhibition Perks

Early-employee stock options 100% Medical, dental, and vision coverage and 50% covered for dependants Flexible hours Partially remote work is available Paid vacation (4 weeks) Talus Bio is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

Why you should join Talus Bio

Gene regulators are responsible for interpreting the human genome by switching genes on and off at the correct time in the correct cells, and their malfunction is common across many diseases. While our tools to measure and manipulate DNA itself have matured (DNAseq, CRISPR), we lack effective tools for studying gene regulators.

As a result, gene regulators are often passed over in favor of protein families with established experimental approaches, leading to few drug candidates for this target class. There are over 2,200 proteins in this family, yet less than 2% of them are targeted with FDA-approved drugs. Many of these approved drugs were discovered by serendipity, so we instead are pursuing a systematic approach for the discovery and development of gene regulator drugs.

Our platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for hundreds of gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.